Bank of Nova Scotia
RARE icon

Bank of Nova Scotia’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bank of Nova Scotia’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-241,985
Closed -$8.8M – 1107
2025
Q2 		$8.8M Buy
+241,985
New +$8.72M 0.02% 410
2023
Q4 		– Sell
-42,451
Closed -$1.51M – 1073
2023
Q3 		$1.51M Buy
+42,451
New +$1.68M ﹤0.01% 632
2023
Q2 		– Sell
-38,200
Closed -$1.53M – 1135
2023
Q1 		$1.53M Sell
38,200
-61,000
-61% -$2.62M ﹤0.01% 606
2022
Q4 		$4.6M Hold
99,200
– – 0.01% 492
2022
Q3 		$4.11M Buy
99,200
+60,897
+159% +$3.13M 0.01% 462
2022
Q2 		$2.28M Buy
+38,303
New +$2.36M 0.01% 661

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Bank of Nova Scotia's RARE Position: Q3 2025 in Review

Bank of Nova Scotia sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 241,985 shares — an estimated $8.8M sold.

Bank of Nova Scotia first reported a position in RARE in Q2 2022 and held it in 6 quarters. The position peaked at $8.8M in Q2 2025. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Bank of Nova Scotia reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Bank of Nova Scotia sold 241,985 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $8.8M.
  • Bank of Nova Scotia first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 6 quarters.
  • Bank of Nova Scotia's Ultragenyx Pharmaceutical position peaked at $8.8M in Q2 2025.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Bank of Nova Scotia's 13F filing for Q3 2025, filed 14 Nov 2025.